SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-13 |
| Reported value | $1,039,007,705 |
| Positions | 15 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Veradermics, Inc. | MANE | Common Stock | $295,285,652 | 2,401,868 |
| Zenas BioPharma, Inc | ZBIO | Common Stock | $127,860,735 | 5,037,854 |
| CRISPR Therapeutics AG | CRSP | Common Shares | $111,194,134 | 2,038,763 |
| Avalyn Pharma, Inc | AVLN | Common Stock | $108,920,725 | 3,308,649 |
| Design Therapeutics, Inc. | DSGN | Common Stock | $94,438,108 | 6,526,476 |
| Odyssey Therapeutics, Inc. | ODTX | Common Stock | $71,002,261 | 3,794,883 |
| Alumis Inc. | ALMS | Common Stock | $55,151,473 | 1,959,896 |
| ORIC Pharmaceuticals, Inc. | ORIC | Common Stock | $49,984,609 | 4,615,384 |
| Mineralys Therapeutics Inc. | MLYS | Common Stock | $42,195,803 | 1,563,966 |
| ARS Pharmaceuticals, Inc. | SPRY | Common Stock | $32,143,353 | 4,012,903 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.